Interested in sharing the research? You can order print copies of many research publications.

Order Reprints

Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

Value in Health Special Issue: Apples and Oranges? Assessing Comparative Effectiveness and Comparative Value in the U.S. and Other Countries

This special issue of Value in Health showcases presentations made at the Apples and Oranges? Assessing Comparative Effectiveness and Comparative Value in the U.S. and Other Countries symposium held on May 15, 2009.

Articles in this issue include the following:

  • Apples and Oranges? Assessing Comparative Effectiveness and Comparative Value in the US and Other Countries (pages S1–S3), Adrian R. Levy and Louis P. Garrison Jr.
  • Health Technology Assessment in the United Kingdom (pages S4–S5), Ron Akehurst
  • Health Technology Assessment and Comparative Effectiveness in Sweden (pages S6–S7), Egon Jonsson
  • Conditionally Funded Field Evaluations: PATHs Coverage with Evidence Development Program for Ontario (pages S8–S11), Ron Goeree, Kiran Chandra, Jean-Eric Tarride, Daria O'Reilly, Feng Xie, James Bowen, Gord Blackhouse and Robert Hopkins
  • Comparative Assessment for Medications and Devices: Apples and Oranges? (pages S12–S14), Scott Ramsey
  • Contemporary Challenges in Deriving Summary Estimates of Comparative Effectiveness Using Meta-Analysis (pages S15–S17), Edward J. Mills
  • Reflecting Heterogeneity in Patient Benefits: The Role of Subgroup Analysis with Comparative Effectiveness (pages S18–S21), Mark Sculpher
  • Transportability of Comparative Effectiveness and Cost-Effectiveness between Countries (pages S22–S25), Andrew Briggs
  • Experimental and Observational Data and Formulary Listing (pages S26–S29), Raulo S. Frear
  • Net Clinical Benefit: The Art and Science of Jointly Estimating Benefits and Risks of Medical Treatment (pages S30–S32), Adrian Towse

Due to copyright issues, articles must be accessed through the Value in Health website. NPC has limited print copies available for order.

Blog Post

CER Tweets of the Week: NPC Survey on Medicaid Directors’ CER Views; EU/USA CER Expectations; #HIMSS15 (April 13-17)

This week, comparative effectiveness research (CER) stakeholders welcomed data from the National Pharmaceutical Council’s (@npcnow) survey assessing...
Blog Post

CER Tweets of the Week: NPC and PCORI at AMCP 27th Annual Meeting & Expo (April 6-10)

This week, comparative effectiveness research (CER) stakeholders tweeted from the Academy of Managed Care Pharmacy’s 27th Annual Meeting and Expo (#...
Press Release

State Medicaid Directors Share Views on Comparative Effectiveness Research And Its Impact on Policy in National Pharmaceutical Council Survey

(Washington, DC, April 16, 2015)—A new survey conducted on behalf of the National Pharmaceutical Council (NPC) shows that state Medicaid directors...
Blog Post

CER Tweets of the Week: NPC in JCER, PCORI Multiple Sclerosis Workshop (March 30 – April 3)

This week, comparative effectiveness research (CER) stakeholders on Twitter shared the Journal of Comparative Effectiveness Research’s (@fsgcer)...
Press Release

State Medicaid Directors Share Views on Comparative Effectiveness Research And Its Impact on Policy in National Pharmaceutical Council Survey

(Washington, DC, April 16, 2015)—A new survey conducted on behalf of the National Pharmaceutical Council (NPC) shows that state Medicaid directors...
Press Release

NPC Highlights Stakeholder Views on Comparative Effectiveness Research and the Environment for Health Care Decision-Making

(Washington, DC, March 26, 2015)—A new survey of health care stakeholders reveals continued optimism that comparative effectiveness research (CER)...
Press Release

NPC Study Outlines When & How Health Decision-Makers Should Consider Individual Patient Differences

Washington, DC (July 29, 2014)—New research led by the National Pharmaceutical Council (NPC) can assist health care stakeholders to understand when...
Press Release

NPC Annual Stakeholder Survey: Comparative Effectiveness Research Is Important, But Impact on Health Care Decision-Making Is Still on the Horizon

(Washington, DC, May 19, 2014)—A new survey of health care stakeholders reveals continued optimism for the use of comparative effectiveness research...
Commentary and Testimony Page

Chain Drug Review – Commentary: “Health Care Outlook for 2015”

This commentary was originally published in the January 5, 2015 issue of Chain Drug Review.By: Dan Leonard, President, National Pharmaceutical...
Commentary and Testimony Page

NPC Comments on PCORI Proposal for Peer Review of Primary Research and Public Release of Research Findings

November 7, 2014Dr. Joe SelbyExecutive DirectorPatient-Centered Outcomes Research Institute1828 L St., NW, Suite 900Washington, DC 20036Dear Dr....
Commentary and Testimony Page

The State of CER and the Environment for Health Care Decision Making

This month, NPC released its third annual survey on stakeholders’ views on comparative effectiveness research (CER), “The State of Comparative...
Commentary and Testimony Page

Keeping Our Eye on the CER Ball

Until the cherry blossoms begin to bloom later next month, most of the water cooler conversations in Washington will focus on the federal budget....
YouTube Videos

Comparative Effectiveness Research and the Environment for Health Care Decision-Making

During a March 26, 2015 webinar, the National Pharmaceutical Council discussed the results of its annual stakeholder survey on comparative...
YouTube Videos

Incorporating Patient Views Into Health Technology Assessments

David Grainger, senior director, global public policy, Eli Lilly and Company, explains that many health technology assessments are incorporating...
YouTube Videos

Health Technology Assessments and Specialty Medications

David Grainger, senior director, global public policy, Eli Lilly and Company, says that there are often challenges in conducting health technology...
YouTube Videos

Differences in Global Health Technology Assessment

David Grainger, senior director, global public policy, Eli Lilly and Company, describes how health technology assessment (HTA) informs policy and...
Blog Post

CER Tweets of the Week: NPC Survey on Medicaid Directors’ CER Views; EU/USA CER Expectations; #HIMSS15 (April 13-17)

This week, comparative effectiveness research (CER) stakeholders welcomed data from the National Pharmaceutical Council’s (@npcnow) survey assessing...
Blog Post

CER Tweets of the Week: NPC and PCORI at AMCP 27th Annual Meeting & Expo (April 6-10)

This week, comparative effectiveness research (CER) stakeholders tweeted from the Academy of Managed Care Pharmacy’s 27th Annual Meeting and Expo (#...
Blog Post

CER Tweets of the Week: NPC in JCER, PCORI Multiple Sclerosis Workshop (March 30 – April 3)

This week, comparative effectiveness research (CER) stakeholders on Twitter shared the Journal of Comparative Effectiveness Research’s (@fsgcer)...
Blog Post

CER Tweets of the Week: NPC’s CER Survey 2015 Webinar, PCORnet to Engage Health Systems (March 23-27)

This week, several comparative effectiveness research (CER) stakeholders participated in a conversation on Twitter during the National Pharmaceutical...
  •  
  • 1 of 13
  • >